Global Recombinant Activated Coagulation Factor VII Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Activated Coagulation Factor VII Market Research Report 2024
Coagulation Factor VIIa, recombinant is a coagulation factor indicated forTreatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
According to Mr Accuracy reports new survey, global Recombinant Activated Coagulation Factor VII market is projected to reach US$ 1529.6 million in 2029, increasing from US$ 1179 million in 2022, with the CAGR of 3.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Activated Coagulation Factor VII market research.
According to the Global Use of Medicines 2024 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2024 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Activated Coagulation Factor VII market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
Segment by Type
Vial
Prefilled Syringe
Hemophilia A
Hemophilia B
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Activated Coagulation Factor VII report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Recombinant Activated Coagulation Factor VII market is projected to reach US$ 1529.6 million in 2029, increasing from US$ 1179 million in 2022, with the CAGR of 3.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Activated Coagulation Factor VII market research.
According to the Global Use of Medicines 2024 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2024 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Activated Coagulation Factor VII market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
Segment by Type
Vial
Prefilled Syringe
Segment by Application
Hemophilia A
Hemophilia B
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Activated Coagulation Factor VII report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices